Robert Dreicer, MD of the University of Virginia Health System discusses the future role of immunotherapy and checkpoint inhibitors in urothelial cancer at ASCO GU 2016.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content